Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Subsequent Primary Malignancies Among Multiple Myeloma Patients Treated with or without Lenalidomide

Dana E Rollison, PhD, Rami Komrokji, MD, Ji-Hyun Lee, PhD, Shalaka S Hampras, PhD, William Fulp, Kate Fisher, MA, Rachid Baz, MD, Taiga Nishihori, MD, Marta Olesnyckyj, Laurie Kenvin, BSN, RN, Robert D. Knight, MD, Daniel M Sullivan, MD, Melissa Alsina, MD, William Dalton, PhD MD, Kenneth H. Shain, MD PhD

Blood (2014) 124 (21): 2129.

https://doi.org/10.1182/blood.V124.21.2129.2129

Published: 2014

Journal Articles

Lenalidomide and Risk of Acute Myeloid Leukemia (AML) Transformation Among Myelodysplastic Syndrome (MDS) Patients

Dana E Rollison, PhD, Kenneth H. Shain, MD PhD, Ji-Hyun Lee, PhD, Shalaka S Hampras, PhD, William Fulp, Kate Fisher, MA, Najla H Al Ali, Eric Padron, MD, Jeffrey Lancet, Qiang Xu, PhD, Robert D. Knight, MD, Alan F. List, MD, William Dalton, PhD MD, Rami Komrokji, MD

Blood (2014) 124 (21): 1912.

https://doi.org/10.1182/blood.V124.21.1912.1912

Published: 2014

Journal Articles

Subsequent Primary Malignancies Among Myelodysplastic Syndrome Patients Treated with or without Lenalidomide

Dana E Rollison, PhD, Kenneth H. Shain, MD PhD, Ji-Hyun Lee, PhD, Shalaka S Hampras, PhD, Kate Fisher, MA, Najla H Al Ali, Eric Padron, MD, Jeff E Lancet, MD, Marta Olesnyckyj, Laurie Kenvin, BSN, RN, Robert D. Knight, MD, William Dalton, PhD MD, Alan F. List, MD, Rami Komrokji, MD

Blood (2014) 124 (21): 413.

https://doi.org/10.1182/blood.V124.21.413.413

Published: 2014

Journal Articles

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

Blood (2012) 120 (23): 4513–4516.

https://doi.org/10.1182/blood-2012-05-426924

Published: 2012

Includes: Supplemental data

Journal Articles

Response Adapted Therapy Using Single Agent Lenalidomide in Older Adults with Newly Diagnosed Standard Risk Multiple Myeloma

Rachid Baz, MD, Melissa Alsina, MD, Kenneth H. Shain, MD, PhD, Jennifer Paleveda, Nancy Hillgruber, RN, Elizabeth Finley-Oliver, RN, Leonel Ochoa, MD, Taiga Nishihori, MD, William Dalton, PhD, MD, Daniel Sullivan, MD

Blood (2012) 120 (21): 4060.

https://doi.org/10.1182/blood.V120.21.4060.4060

Published: 2012

Journal Articles

Oral Weekly Cyclophosphamide in Combination with Pomalidomide and Dexamethasone for Relapsed and Refractory Myeloma: Report of the Dose Escalation Cohort

Rachid Baz, MD, Kenneth H. Shain, MD, PhD, Melissa Alsina, MD, Lisa A Nardelli, Taiga Nishihori, MD, Leonel Ochoa, MD, Thomas Martin, MD, Sundar Jagannath, MD, William Dalton, PhD, MD, Daniel M Sullivan, MD

Blood (2012) 120 (21): 4062.

https://doi.org/10.1182/blood.V120.21.4062.4062

Published: 2012

Journal Articles

Updated Results of Phase II Study of Cyclophosphamide(Cy), Bortezomib(Bz), Pegylated Doxorubicin(DOX), and Dexamethasone(dex), (CVDD), in Patients with Newly Diagnosed Myeloma:an Effective Induction Regimen for High Risk Disease

Melissa Alsina, MD, Rachid Baz, MD, Kenneth H. Shain, MD, PhD, Leonel Ochoa, MD, Taiga Nishihori, MD, Daniel M Sullivan, MD, Binglin Yue, Jongphil Kim, PhD, William Dalton, PhD, MD

Blood (2012) 120 (21): 4071.

https://doi.org/10.1182/blood.V120.21.4071.4071

Published: 2012

Journal Articles

Rational Drug Design: Proteasome Inhibitor Mediated Down-Regulation of the FA/BRCA Pathway Is Synergistic with PARP Inhibition in Myeloma Cell Lines

Liang Nong, M.D., Linda Mathews, Mark B Meads, Ph.D., William Dalton, PhD, MD, Kenneth H. Shain, MD, PhD

Blood (2011) 118 (21): 2922.

https://doi.org/10.1182/blood.V118.21.2922.2922

Published: 2011

Journal Articles

Characterization of Clonotypic B Cell Progenitors in Bone Marrow of Multiple Myeloma Patients,

Kelly Boucher, BA, Nancy Parquet, BS, Kenneth H. Shain, MD, PhD, Rachid Baz, MD, Melissa Alsina, MD, John Koomen, Ph.D., Ashley Durand, Claudio Anasetti, MD, William Dalton, PhD, MD, Lia Perez, MD

Blood (2011) 118 (21): 4002.

https://doi.org/10.1182/blood.V118.21.4002.4002

Published: 2011

Journal Articles

Sequence of Therapy in Multiple Myeloma: Does It Matter? Retrospective Evaluation of Patients with Multiple Myeloma Who Have Received Bortezomib Followed by Lenalidomide or Vice Versa,

Amila M Patel, PharmD, Viet Q. Ho, PharmD, BCOP, Kenneth H. Shain, MD, PhD, Daniel Sullivan, MD, Melissa Alsina, MD, Leonel Ochoa, Taiga Nishihori, MD, Benjamin Djulbegovic, MD, PhD, William Dalton, PhD, MD, Rachid Baz, MD

Blood (2011) 118 (21): 3979.

https://doi.org/10.1182/blood.V118.21.3979.3979

Published: 2011

Journal Articles

Microenvironment-Mediated Bim Down-Regulation through Induction of Microrna-181a Protects Cells From Apoptosis In Mantle-Cell and Other Non-Hodgkin B-Cell Lymphomas

Tint Lwin, MD, PhD, Jian-Hong Lin, MD, Yong Sung Choi, MD, PhD, Xinwei Zhang, MD, Lynn Moscinski, MD, Kenneth Wright, PhD, Eduardo M. Sotomayor, MD, William Dalton, PhD, MD, Jianguo Tao, MD, PhD

Blood (2010) 116 (21): 3118.

https://doi.org/10.1182/blood.V116.21.3118.3118

Published: 2010

Journal Articles

Bortezomib Targets Stroma-Mediated APO2L/TRAIL Apoptosis Resistance in Multiple Myeloma.

Lia Perez, MD, Nancy Parquet, Claudio Anasetti, William Dalton

Blood (2008) 112 (11): 1665.

https://doi.org/10.1182/blood.V112.11.1665.1665

Published: 2008

Journal Articles

Phase I Study of Bortezomib, (BTZ) Followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL).

Todd Alekshun, MD, Christine Mcisaac-Simonelli, RN, Mohamed Kharfan-Dabaja, MD, William Dalton, MD, PhD, Benjamin Djulbegovic, MD, Hugo Fernandez, MD, Daniel M. Sullivan, MD, Ernesto Ayala, MD, Teresa L. Field, MD, Dawn Garrett, LPN, William E. Janssen, PhD, Beth Maddox, RN, Lia Perez, MD, Dawn Kettner, PA, Janelle Perkins, PharmD, Jyoti Raychaudhuri, MD, Claudio Anasetii, MD, Melissa Alsina, MD

Blood (2007) 110 (11): 5131.

https://doi.org/10.1182/blood.V110.11.5131.5131

Published: 2007

Journal Articles

Environmental Mediated-Immune Resistance (EM-IR) to APO2L/TRAIL Mediated Apoptosis.

Lia E. Perez, MD, Nancy Parquet, BS, Marina Molisano, BS, Ken Shain, Ph.D, Melisa Alsina, MD, Claudio Anasetti, MD, William Dalton, Ph.D. MD

Blood (2007) 110 (11): 3521.

https://doi.org/10.1182/blood.V110.11.3521.3521

Published: 2007

Journal Articles

Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM).

Daniel Sullivan, MD, Melissa Alsina, MD, Claudio Anasetti, MD, Teresa Field, MD, PhD, Mohamed Kharfan-Dabaja, MD, Hugo Fernandez, MD, William Dalton, PhD, MD, Ernesto Ayala, MD, Jyoti Raychaudhuri, MD, Lia Perez, MD, Janelle Perkins, PharmD, Michael Schell, PhD, Christine McIsaac, RN, Beth Maddox, RN, Jana Gump, BS, Richard Lush, PhD, Tony Frudakis, PhD

Blood (2007) 110 (11): 943.

https://doi.org/10.1182/blood.V110.11.943.943

Published: 2007

Journal Articles

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

Blood (2007) 110 (10): 3557–3560.

https://doi.org/10.1182/blood-2006-08-036947

Published: 2007

Includes: Supplemental data

Journal Articles

Microenvironment Confers Resistance to TRAIL Mediated Apoptosis.

Lia E. Perez, MD, Nancy Parquet, BS, Ramadevi Nimmanapalli, DVM, PhD, Melissa Alsina, M.D, Claudio Anasetti, MD, William Dalton, PhD MD

Blood (2005) 106 (11): 2489.

https://doi.org/10.1182/blood.V106.11.2489.2489

Published: 2005

Journal Articles

Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells

Kuichun Zhu, Elvira Gerbino, Darrin M. Beaupre, Paul A. Mackley, Carlos Muro-Cacho, Craig Beam, Andrew D. Hamilton, Mathias G. Lichtenheld, William G. Kerr, William Dalton, Melissa Alsina, Saïd M. Sebti

Blood (2005) 105 (12): 4759–4766.

https://doi.org/10.1182/blood-2004-11-4307

Published: 2005

Journal Articles

Bortezomib Partially Overcomes TNF-Related Apoptosis Inducing ligand/Apo-2L (TRAIL/Apo-2L) Environment Mediated-Drug Resistance (EM-DR).

Nancy Parquet, B.S., Ramadevi Nimmanapalli, D.V.M. Ph.D., Claudio Anasetti, M.D., Melissa Alsina, M.D., William Dalton, Ph.D. M.D., Lia E. Perez, M.D.

Blood (2004) 104 (11): 2459.

https://doi.org/10.1182/blood.V104.11.2459.2459

Published: 2004

NARROW

Subsequent Primary Malignancies Among Multiple Myeloma Patients Treated with or without Lenalidomide

Lenalidomide and Risk of Acute Myeloid Leukemia (AML) Transformation Among Myelodysplastic Syndrome (MDS) Patients

Subsequent Primary Malignancies Among Myelodysplastic Syndrome Patients Treated with or without Lenalidomide

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

Response Adapted Therapy Using Single Agent Lenalidomide in Older Adults with Newly Diagnosed Standard Risk Multiple Myeloma

Oral Weekly Cyclophosphamide in Combination with Pomalidomide and Dexamethasone for Relapsed and Refractory Myeloma: Report of the Dose Escalation Cohort

Updated Results of Phase II Study of Cyclophosphamide(Cy), Bortezomib(Bz), Pegylated Doxorubicin(DOX), and Dexamethasone(dex), (CVDD), in Patients with Newly Diagnosed Myeloma:an Effective Induction Regimen for High Risk Disease

Rational Drug Design: Proteasome Inhibitor Mediated Down-Regulation of the FA/BRCA Pathway Is Synergistic with PARP Inhibition in Myeloma Cell Lines

Characterization of Clonotypic B Cell Progenitors in Bone Marrow of Multiple Myeloma Patients,

Sequence of Therapy in Multiple Myeloma: Does It Matter? Retrospective Evaluation of Patients with Multiple Myeloma Who Have Received Bortezomib Followed by Lenalidomide or Vice Versa,

Microenvironment-Mediated Bim Down-Regulation through Induction of Microrna-181a Protects Cells From Apoptosis In Mantle-Cell and Other Non-Hodgkin B-Cell Lymphomas

Bortezomib Targets Stroma-Mediated APO2L/TRAIL Apoptosis Resistance in Multiple Myeloma.

Phase I Study of Bortezomib, (BTZ) Followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL).

Environmental Mediated-Immune Resistance (EM-IR) to APO2L/TRAIL Mediated Apoptosis.

Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM).

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

Microenvironment Confers Resistance to TRAIL Mediated Apoptosis.

Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells

Bortezomib Partially Overcomes TNF-Related Apoptosis Inducing ligand/Apo-2L (TRAIL/Apo-2L) Environment Mediated-Drug Resistance (EM-DR).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only